Literature DB >> 7531099

Soluble CD14 is increased in bronchoalveolar lavage of active sarcoidosis and correlates with alveolar macrophage membrane-bound CD14.

I Striz1, L Zheng, Y M Wang, H Pokorná, P C Bauer, U Costabel.   

Abstract

CD14 is a myeloid differentiation antigen which exists in a membrane-bound (55 kD) and a soluble (48 kD) form. This antigen is a receptor for lipopolysaccharide (LPS) structures and triggers the production of various cytokines. The aim of this study was to evaluate whether in active sarcoidosis, a disease with increased proportions of alveolar macrophages (AM) with CD14 expression in BAL fluid, the soluble form of CD14 (sCD14) is also increased. The sCD14 levels were measured in BAL fluid with an ELISA, and membrane-bound CD14 was determined by an immunoperoxidase assay, in active sarcoidosis (n = 13), inactive sarcoidosis (n = 9), idiopathic pulmonary fibrosis (IPF) (n = 6), and control subjects (n = 8). Higher concentrations of sCD14 were present in BAL fluid of patients with active sarcoidosis (58 +/- 34 ng/ml) than in those with inactive disease (13 +/- 10 ng/ml), patients with IPF (5 +/- 5 ng/ml), or control subjects (10 +/- 8% ng/ml) (p < 0.01). Similarly, the proportions of AM expressing membrane-bound CD14 were increased in active sarcoidosis (91 +/- 6%) compared with inactive sarcoidosis (82 +/- 6%), patients with IPF (76 +/- 13%), and control subjects (79 +/- 9%) (p < .05). In sarcoidosis, a significant correlation was found between the sCD14 concentration in BAL fluid and AM membrane expression of CD14 (r = 0.57, p < 0.01). We conclude that sCD14 is increased in BAL of active sarcoidosis suggesting a potential role for this substance as marker of activity and in the pathogenesis of pulmonary sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531099     DOI: 10.1164/ajrccm.151.2.7531099

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  7 in total

1.  Linkage between Toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosis.

Authors:  M Veltkamp; P A H M Wijnen; C H M van Moorsel; G T Rijkers; H J T Ruven; M Heron; O Bekers; A M E Claessen; M Drent; J M M van den Bosch; J C Grutters
Journal:  Clin Exp Immunol       Date:  2007-06-12       Impact factor: 4.330

2.  Dual Inhibition of Rip2 and IRAK1/4 Regulates IL-1β and IL-6 in Sarcoidosis Alveolar Macrophages and Peripheral Blood Mononuclear Cells.

Authors:  Jaya Talreja; Harvinder Talwar; Nisar Ahmad; Ruchi Rastogi; Lobelia Samavati
Journal:  J Immunol       Date:  2016-07-11       Impact factor: 5.422

Review 3.  Soluble CD14: role in atopic disease and recurrent infections, including otitis media.

Authors:  Karin C Lødrup Carlsen; Berit Granum
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

4.  CD14 expression and binding of lipopolysaccharide to alveolar macrophages and monocytes.

Authors:  T S Haugen; B Nakstad; O H Skjønsberg; T Lyberg
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

5.  Expression, regulation and clinical significance of soluble and membrane CD14 receptors in pediatric inflammatory lung diseases.

Authors:  Veronica Marcos; Phillip Latzin; Andreas Hector; Sebastian Sonanini; Florian Hoffmann; Martin Lacher; Barbara Koller; Philip Bufler; Thomas Nicolai; Dominik Hartl; Matthias Griese
Journal:  Respir Res       Date:  2010-03-19

6.  Imbalance of pro- and anti-inflammatory cytokines in pulmonary sarcoidosis.

Authors:  J Müller-Quernheim
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

7.  Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia.

Authors:  Maria Antonella Zingaropoli; Parni Nijhawan; Anna Carraro; Patrizia Pasculli; Paola Zuccalà; Valentina Perri; Raffaella Marocco; Blerta Kertusha; Guido Siccardi; Cosmo Del Borgo; Ambrogio Curtolo; Camilla Ajassa; Marco Iannetta; Maria Rosa Ciardi; Claudio Maria Mastroianni; Miriam Lichtner
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.